TFF/Belmay terminate proposed merger
This article was originally published in The Rose Sheet
Executive Summary
Fragrance developer Technology Flavors & Fragrances and fragrance supplier Belmay have terminated proposed merger discussions in a mutual agreement, the two companies announce Jan. 16. "Although the TFF/Belmay combination would have created a much larger entity in terms of sales volume...the proposed merger was not in the interest of our shareholders," Amityville, N.Y.-based TFF states. The two firms entered into the proposed agreement in November; merger was projected to result in combined sales of $60 mil. for the two firms (11"The Rose Sheet" Nov. 26, 2001, In Brief)...
You may also be interested in...
Belmay/TFF merger
New York City-based fragrance supplier Belmay and Amityville, N.Y.-based fragrance developer Technology Flavors & Fragrances will have combined sales of more than $60 mil. following planned merger announced Nov. 20. Agreement would call for Belmay to purchase 75% of TFF, which would change its name to Belmay/TFF and reconstitute its board of directors, firm says. Belmay President/CEO Ted Kesten will be appointed chairman/CEO of combined entity, while TFF Chairman/CEO Philip Rosner will become vice chair. Merger will help transform TFF into "world-class global developer and manufacturer of flavors and fragrances" by providing access to Belmay's solid infrastructure and international operations, TFF says. Move follows restructuring announcement by TFF prompted by consecutive sales losses ("The Rose Sheet" Nov. 19, In Brief)...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.